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ABSTRACT
BACKGROUND: A pterygium is a fibrovascular overgrowth of degenerative bulbar
conjunctival tissue that grows over the limbus onto the cornea. Although various
approaches have been proposed for the treatment of pterygium, the common problem
after these treatments is recurrence.
OBJECTIVES: The goals of this study were to compare the efficacy of mitomycin C
(MMC) and limbal-conjunctival autograft (LCAD) in preventing recurrence of primary
pterygia and to monitor long-term adverse effects (AEs).
METHODS: Patients undergoing pterygium surgery between February 2006 and
May 2007 were assessed prospectively and randomly divided into 2 groups using a random
number table. The MMC group underwent pterygium excision and received 0.02% MMC
intraoperatively for 2 minutes. The LCAD group underwent pterygium excision and
LCAD. Recurrence and AE rates of the 2 treatments were compared during the 1-year
follow-up period. Assessors for pterygial recurrence were masked to treatment group.
RESULTS: One hundred thirteen eyes (57 patients in the MMC group and 56 pa-
tients in the LCAD group) were included in the study. Thirteen of the patients (7 in
the MMC group and 6 in the LCAD group) were withdrawn due to irregular atten-
dance at follow-up visits or lack of sufficient dose and duration for postoperative
topical antibiotic and steroid administration; their data were excluded from analysis.
Fifty patients (MMC group: 26 men, 24 women; mean [SD} age, 48.0 [l2.3} years;
age range, 30-73 years; LCAD group: 27 men, 23 women; mean age, 49.0 [l2.6} years;
age range, 28-71 years) in each group completed the study. The mean (SD) length of
the pterygium across the limbus was similar in the MMC group and the LCAD group
(4.18 [1.27) vs 4.07 [1.24} mm). The mean follow-up period was also similar in the
2 groups (16.0 [1.9} vs 15.0 [1.7} months). The rate of recurrence was significantly
greater in the MMC group than in the LCAD group (10 [20.0%} vs 2 [4.0%} patients;
P = 0.035). Seven patients (14.0%) in the MMC group experienced AEs: conjunctival
cyst (3 patients), symblepharon (2), conjunctival granuloma (1), and dellen (1). In
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the LCAU group, 1 patient (2.0%; P = 0.032 vs MMC group) experienced perma-
nent graft edema. All patients in the LCAU group experienced transient graft edema,
with recovery occurring in 3 to 4 weeks. There were no intraoperative complications
and there was no graft rejection.
CONCLUSIONS: Recurrence and postoperative AEs were less frequently observed
in primary excision with LCAU than with MMC in these Turkish patients who com-
pleted the study. This study found that pterygium excision with LCAU was well
tolerated and effective in these patients. (Curr Ther Res Clin Exp. 2009;70:274-281)
© 2009 Excerpta Medica Inc.
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INTRODUCTION
A pterygium is a fibrovascular overgrowth of degenerative bulbar conjunctival tissue
growing over the limbus onto the cornea. The disease occurs worldwide, although it
is particularly common in tropical and subtropical countries. 1 Pterygium causes
chronic irritation, impaired cosmetic appearance, and decreased vision secondary to
growth over the pupillary axis, induced astigmatism, or disruption of the precorneal
tear film. 2 Although various approaches (eg, surgical procedures, B-irradiation, laser
treatments, and medications) have been proposed for the treatment of pterygium, a
common problem after these treatments is recurrence. 3 Recurrence rates of simple
excision without adjuvant treatment in pterygium surgery have been reported to be
24% to 89%.4
Mitomycin C (MMC) is an alkalizing agent that inhibits DNA synthesis, resulting
in long-term inhibition of Tenon's fibroblast proliferation.s MMC has been reported
to be effective in preventing pterygial recurrence. S- 7 Its use in pterygium surgery was
first reported in]apan in 19638 and in the United States in 1988.9 Since then, it has
been described in numerous studies as an effective adjunct in reducing the recurrence
rate of pterygium after excision.s-7 ,9 However, serious complications varying from
scleral thinning to scleral necrosis have been observed after the use of MMC. 10
Limbal-conjunctival autograft (LCAU) is an alternative adjuvant treatment in
pterygium surgery.ll Conjunctival autografting is time consuming and requires a
significant learning curve,12 but it may be the preferred approach because it is not
associated with MMC-related adverse effects (AEs).13 In 1985, Kenyon et aI14 reported
the first study using conjunctival autograft transplantation. The authors found a
7.3% secondary recurrence rate in patients with recurrent pterygium, whereas there
was no recurrence with primary pterygium. Using the same technique, Lewallen1s
reported a 21% recurrence rate for primary pterygium. In 1989, Tseng 16 reported the
limbus to be a distinct cellular structure, lying between the corneal and conjunctival
epithelium, that contains stem cells that are vital for normal corneal epithelial regen-
eration and that prevent the growth of conjunctival epithelium onto the cornea
through contact inhibition.
Although the pathogenesis of pterygium is still unclear, destruction of limbal stem
cells by ultraviolet light exposure can result in pterygiaY Because limbal stem-cell
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lllJury is considered an etiologic factor of pterygium, stem cell transplantation by
LCAD is recommended for both primary and recurrent pterygiaY For this reason,
LCAD has been recommended to prevent recurrences in primary and recurrent pterygi-
um surgeryY Recurrence rates after LCAD have been reported to be 2% to 33% in
primary and recurrent pterygial surgery.18-20 Limbal stem cells prohibit excessive
proliferation of conjunctival tissue and act like a barrier against the development of
pterygia. The inclusion of limbal epithelium in a conjunctival graft restores the bar-
rier function of the limbus. Studies have reported the effectiveness of LCAD in pre-
venting pterygial recurrence. 14-16 LCAD has been reported to be more effective than
MMC in the prevention of recurrence in pterygium surgery, suggesting that LCAD
might reduce rates of recurrence and complications. 21
The goals of this study were to compare the efficacy ofMMC and LCAD in prevent-
ing recurrence of primary pterygia and to monitor long-term AEs.
PATIENTS AND METHODS
This study was conducted in accordance with the Declaration of Helsinki. Written in-
formed consent was obtained from all participants prior to enrollment. Institution-
al review board approval was obtained from Diyarbakir Training and Research Hos-
pital (Diyarbakir, Turkey).
Patients were eligible for the study if they were aged >25 years and had a primary
fleshy or growing pterygium that invaded >2 mm into the cornea. Patients were ex-
cluded from the study if they had a history of pterygium surgery, limbal stem-cell
failure, ocular-surface disease, atrophic primary pterygium, previous limbal surgery,
double-head pterygium, dry eyes, significant blepharitis, or any ocular, immune, or
systemic disease.
Consecutive patients who met the inclusion criteria and who were undergoing exci-
sion of a primary pterygium between February 2006 and May 2007 were randomized
into 2 treatment groups using a random number table.
Preoperatively, each patient underwent a detailed examination that included visual
acuity, intraocular pressure, extraocular movements, biomicroscopy, documentation of
pterygium size, and dilated funduscopy. On completion of pterygium excision, pa-
tients in 1 group received a single intraoperative dose of 0.02% MMC (0.2 mg/mL)
for 2 minutes; patients in the other group underwent an LCAD.
One surgeon (~.A.) performed the MMC procedures and another (Z.O.Y.) con-
ducted the LCAD procedures, all of which were performed on an outpatient basis. The
procedure included topical anesthesia with 0.4% benoxinate hydrochloride. In the
MMC group, the pterygium head was excised from the cornea with a disposable cres-
cent knife. The conjunctival epithelium covering the body of the pterygium was sepa-
rated from the pterygium body with spring-action scissors. The pterygium body was
then separated from the episclera and the medial rectus fascia and excised, leaving the
overlying conjunctiva intact. A sponge soaked in a solution of MMC 0.2 mg/mL
was applied to the excisional area for 2 minutes. This was followed by copious
irrigation of the space between the conjunctiva and the sclera with 20 to 30 mL
of balanced saline solution. The conjunctiva was then sutured to the sclera with
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~2 separated 10-0 polyglactin sutures, leaving an area of 2 mm of bare sclera between
the conjunctival edge and the limbus.
In the LCAD group, the pterygium was separated from the cornea using a dis-
posable knife. Conjunctival tissue was dissected. Pterygial tissue and subconjunctival
Tenon's capsule was excised and the recipient bed was prepared for graft application.
A free conjunctival graft prepared from superotemporal conjunctival tissue was dis-
sected from the limbus at a thickness of 1 mm along the cornea. The LCAD was 1 mm
wider than the recipient bed and the limbus was sutured using 10-0 nylon suture
material.
After surgery, each patient was treated with a topical corticosteroid (prednisolone
acetate 1%) 4 times daily; the corticosteroids were tapered and discontinued after
3 months. A topical antibiotic (ciprofloxacin) was used until epithelialization of the
wound was complete. The topical corticosteroid and antibiotic therapies were the
same for both groups, as was the follow-up. Patients were examined on days 1,7,15,
30, and 90 and then at 3-month intervals for ~ 1 year. Recurrence of the pterygium
was assessed by another researcher (1.<::.) who was masked to the treatment group.
Slit-lamp biomicroscopy was performed to evaluate the final clinical outcome after
pterygium surgery. Pterygial recurrence was graded using a 4-point scale22 : 1 = normal
appearance of the surgical site; 2 = the presence of fine episcleral vessels in the excised
area extending to the limbus, but without any fibrous tissue; 3 = fibrovascular tissue
in the excised area reaching to the limbus, but not invading the cornea; and 4
a true corneal recurrence, with fibrovascular tissue invading the cornea.
STATISTICAL ANALYSIS
The t test was used to analyze recurrence rates. P < 0.05 was considered statistical-
ly significant. Only the patients who completed the study were included in the
analysis.
RESULTS
One hundred thirteen eyes (57 patients in the MMC group; 56 patients in the LCAD
group) were included in the study. Thirteen of the patients (7 in the MMC group;
6 in the LCAD group) were withdrawn due to irregular attendance at follow-up visits
or lack of sufficient dose and duration for postoperative topical antibiotic and steroid
administration. Fifty patients (MMC group: 26 men, 24 women; mean [SD} age, 48.0
[l2.3} years; age range, 30-73 years; LCAD group: 27 men, 23 women; mean age, 49.0
[l2.6} years; age range, 28-71 years) in each group completed the study. The 2 groups
were similar in terms of demographic and clinical characteristics. The mean (SD)
length of the pterygium across the limbus was similar in the MMC group and the
LCAD group (4.18 [1.27) vs 4.07 [1.24} mm). The mean follow-up period was also
similar in the 2 groups (16.0 [1.9} vs 15.0 [1.7} months) (Table 1).
The rate of recurrence for pterygium was significantly higher in the MMC group
than the LCAD group (10 [20%} vs 2 [4%} patients; P = 0.035). In the MMC group,
pterygium recurrence was observed at month 3 in 1 patient, month 6 in 4 patients,
month 8 in 3 patients, and month 12 in 2 patients. In the LCAD group, recurrence
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Table I. Demographic and clinical characteristics of Turkish patients undergoing pte-
rygial excision with intraoperative mitomycin C (MMC) or Iimbal-conjunctival
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was observed in 2 patients at month 3 (Table II). According to the 4-point recurrence
scale, the 10 patients in the MMC group and 2 patients in the LCAD group who
experienced recurrence were classified as follows: in the MMC group, 6 patients
were grade 2, 3 patients were grade 3, and 1 patient was grade 4; in the LCAD
group, 2 patients were grade 3.
In the MMC group, AEs were observed in 7 patients: conjunctival cyst (3 patients),
symblepharon (2), conjunctival granuloma (1), and dellen (1). One patient in the
LCAD group was found to have an AE (permanent graft edema) (Table III). None of
the AEs were considered serious (eg, scleral thinning or scleral necrosis).
No intraoperative complications occurred in either group. All patients in both
groups had mild symptoms of slight ocular pain, foreign body sensation, lacrimation,
and photophobia during the first week after surgery. Postoperatively, patients in the
LCAD group had mild to moderate edema that subsided within the first 3 to 4 weeks.
Sutures were removed after 3 to 4 weeks when anastomotic vessels were found sur-
rounding the graft. Subconjunctival hemorrhage subsided within 2 to 3 weeks in all
patients and did not affect the conjunctival autograft outcome in any patient.
DISCUSSION
Pterygium surgery has changed over the past decade, and several techniques are now
available. Our study presents some of these techniques, which were used at our insti-
tute, and reflects our efforts to improve the efficacy of the procedure by minimizing
the recurrence rate and to address concerns regarding the tolerability of MMC.
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Table II. Number of pterygiaI recurrences in Turkish patients who
underwent pterygial excision with intraoperative mitomycin C



















MMC is one of the modalities used to reduce the recurrence rate in modern pterygi-
um surgery.23 Intraoperative application of MMC is effective, and the drug is used
regularly by ophthalmologists. 23 MMC acts as an alkalizing agent that causes irrevers-
ible damage to the DNA structures of the cell. Administration of intraoperative MMC
diminishes recurrence rates by avoiding fibrovascular proliferation. 24 In pterygium
surgery, daily administration and single intraoperative use of a variety of MMC doses
have been reported. 24 However, the dose of MMC that can prevent pterygial recur-
rence without causing complications is still unknown. Postoperative use of topical
MMC is not recommended because of possible drug misuse, which may be associated
with severe ocular complications (eg, scleromalacia, corneal perforation, glaucoma, iri-
tis, pain, and punctate keratopathy).25 Single intraoperative use of MMC is better
tolerated than postoperative topical daily application. 25 All patients with an abnormal
ocular surface placing them at increased risk for a delay of epithelialization or for
Table III. Postoperative adverse effects (AEs) in Turkish patients who
underwent pterygial excision with intraoperative mitomycin C


























*Ocular pain, foreign body sensation, and photophobia were transient AEs.
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excessive inflammation (eg, patients with immune disorders, blepharitis, or dry eyes)
were excluded from our study in an attempt to avoid severe ocular complications.
Furthermore, we observed the patients closely until epithelialization of the ocular
surface was complete. 25
The per-protocol design was a limitation of this study; 13 of the 113 patients who
entered the study did not complete it. The small sample size was also a limitation.
Further long-term, multicenter, randomized trials are needed to determine the best
treatment method.
CONCLUSIONS
Recurrence and postoperative complications were less frequently observed in primary
excision with LCAD than with MMC in these Turkish patients who completed the
study. This study found that pterygium excision with LCAD was well tolerated and
effective in these patients.
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